CORONA Remedies Limited has informed the Exchange regarding Change in Director(s) of the company.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies Limited held its Board meeting on May 11, 2026 and approved the audited standalone and consolidated financial results for Q4 and full year ended March 31, 2026. The company reported total income of Rs. 1,413.83 crores for FY26 (up 17.6% from Rs. 1,202.35 crores in FY25) and net profit of Rs. 184.85 crores (up 24% from Rs. 149.05 crores). The Board recommended a 100% final dividend of Rs. 10 per share (record date June 19, 2026). The company also proposed appointment of Walker Chandiok & Co LLP as new statutory auditor for 5 years (subject to AGM approval), replacing Deloitte Haskins & Sells LLP. Additionally, Dr. Kirtikumar Mehta was recommended for reappointment as Non-Executive Chairman for another 5 years from April 2027. The company listed on NSE/BSE in December 2025 via an IPO.
The financial performance shows strong growth with 17.6% revenue increase and 24% profit growth. The auditor change signals a strategic shift in audit firms after the IPO. The 100% dividend payout is positive for shareholders, reflecting management confidence in cash generation.